Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
The firm is currently investigating Pradaxa bleeding lawsuits on behalf of individuals who suffered life-threatening hemorrhaging, allegedly due to Pradaxa.
New York, NY (PRWEB) February 02, 2013
Pradaxa lawsuits continue to move forward in the U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court records, the next status conference in the federal Pradaxa litigation is scheduled for February 7th at 9:00 a.m. More than 170 lawsuits have been filed in the litigation by plaintiffs who allegedly suffered serious, life-threatening episodes of Pradaxa bleeding. All of the complaints accuse Boehringer Ingelheim of selling the blood thinner despite knowing it could cause fatal bleeding in some patients, and failing to adequately warn that there was no readily-available antidote for Pradaxa bleeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation — MDL No. 2385)
“We look forward to more progress in this litigation. Our firm continues to hear from Pradaxa patients who experienced frightening episodes of bleeding while using this blood thinner,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa side effects.
Pradaxa, which is used to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation, was approved by the U.S. Food & Drug Administration (FDA) in October 2010. The drug was supposed to be an alternative to warfarin, a blood thinner that has been on the market for decades. According to the latest QuarterWatch Report from the Institute for Safe Medicine Practices (ISMP), an analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.*
According to a recent report from Bloomberg.com, regulators in several countries have issued Pradaxa safety alerts since the drug was first brought to market.** Most recently, the FDA released a Drug Safety Communication announcing a new contraindication was being added to the Pradaxa label to warn against its use in patients with mechanical heart valves. The FDA acted after participants in a study who were treated with the blood thinner experienced more strokes, heart attacks, and blood clots forming on the mechanical heart valves compared to users of warfarin. There was also more Pradaxa bleeding reported after valve surgery compared to warfarin bleeding, according to the agency.***
Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more please visit the firm´s Pradaxa lawsuit http://www.pradaxalawsuithelp.com/ website, or call 1-877-779-1414 to speak with an attorney today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuit/pradaxa-bleeding/prweb10390263.htm